ReviewAdvances in chronic kidney disease2019
Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus.
Review in Advances in chronic kidney disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- A nomogram predicting the histologic activity of lupus nephritis from clinical parameters.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Trial
- Pathogenesis, Treatment Advances, and Renal Outcomes in Childhood-Onset Lupus Nephritis.Clinical pediatrics · 2026Review
- In reply: epidemiology of immune-mediated thrombotic thrombocytopenic purpura in Germany.Research and practice in thrombosis and haemostasis · 2026Article
- Caveolin-1 as a Marker of Endothelial Damage in Primary Antiphospholipid Syndrome Nephropathy.Kidney medicine · 2026Article
- Effects of disease severity-based nursing intervention on immune function and IFN-γ, IL-6, and TNF-α for children with IgA vasculitis nephritis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Development of a predictive model for nafamostat mesylate dosing in hemodialysis.BMC nephrology · 2025Article
- Kidney transplantation in Lupus Nephritis: a comprehensive review of challenges and strategies.BMC surgery · 2025Review
- Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome.Frontiers in immunology · 2025Review
- Lupus Nephritis Biomarkers: A Critical Review.International journal of molecular sciences · 2024Review
- Case report: Thrombotic thrombocytopenic purpura in a pregnant woman with lupus membranous nephropathy: a diagnostic challenge.Frontiers in nephrology · 2024Article
- Pregnancy as a susceptible state for thrombotic microangiopathies.Frontiers in medicine · 2024Review
- Case report: Rituximab combined with plasma exchange treatment for systemic lupus erythematosus complicated with thrombotic microangiopathy and non-cirrhotic portal hypertension.Frontiers in immunology · 2024Article
- A Contemporary Update on the Diagnosis of Systemic Lupus Erythematosus.Clinical reviews in allergy & immunology · 2022Review
- Kidney thrombotic microangiopathy in lupus nephritis: Impact on treatment and prognosis.Lupus · 2022Article
- Coexistence of thrombotic thrombocytopenic purpura and adult-onset Still's disease.Clinical case reports · 2022Article
- Thrombotic microangiopathy in a patient with systemic lupus erythematosus and anti-factor H autoantibodies.CEN case reports · 2022Article
- Renal thrombotic microangiopathy associated to worse renal prognosis in Lupus Nephritis.Journal of nephrology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Antiphospholipid syndrome (APS) and other causes of thrombotic microangiopathy (TMA) negatively impact the renal outcomes of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Here we review the diagnosis and management of occlusive renal vascular lesions due to APS and other TMAs, with a focus on patients with SLE and lupus nephritis. The presence of a thrombotic event, unexplained hypertension, thrombocytopenia, or hemolytic anemia should prompt consideration for TMA syndromes. The differential diagnosis of a TMA in a patient with SLE includes APS, thrombocytopenic purpura, complement-mediated or infection-associated hemolytic uremic syndrome, drug-mediated TMA (particularly due to calcineurin inhibitor toxicity), and malignant hypertension. Treatment of APS with a documented thrombotic event focuses on anticoagulation to reduce the risk for further thrombotic events. Treatment of classic presentations of thrombocytopenic purpura and hemolytic uremic syndrome in the SLE population is the same as in patients without SLE. Treatment of APS nephropathy or TMA when it is diagnosed by biopsy with concomitant lupus nephritis presents a challenge to clinicians because there is no clear standard of care. Small and retrospective studies suggest potential benefit of complement inhibition, mammalian target of rapamycin (mTOR) inhibition, B cell depleting therapy, and plasma exchange therapy for patients with lupus nephritis and TMA, and prospective investigation of these therapies should be a research priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.